Ken Griffin Cassava Sciences Inc Transaction History

Citadel Advisors LLC

$483 Billion
Q2 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Cassava Sciences Inc stock. As of the latest transaction made, Citadel Advisors LLC holds 66,600 shares of SAVA stock, worth $1.8 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

66,600

Previous 61,000 9.18%

Holding current value

$1.8 Million

Previous $1.24 Million 33.55%

% of portfolio

0.0%

Previous 0.0%

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$12.35 - $26.11 $405,512 - $857,321	32,835 Added 763.25%	37,137 $458,000
Q1 2024 May 15, 2024	BUY	$18.44 - $26.41 $79,328 - $113,615	4,302 New	4,302 $87,000
Q3 2023 Nov 14, 2023	SELL	$16.64 - $25.32 $2.38 Million - $3.62 Million	-143,107 Reduced 94.21%	8,798 $146,000
Q2 2023 Aug 14, 2023	BUY	$21.59 - $27.88 $294,660 - $380,506	13,648 Added 9.87%	151,905 $3.72 Million
Q1 2023 May 15, 2023	BUY	$23.46 - $36.44 $2.49 Million - $3.86 Million	106,023 Added 328.92%	138,257 $3.33 Million
Q4 2022 Feb 14, 2023	BUY	$27.82 - $44.16 $896,749 - $1.42 Million	32,234 New	32,234 $952,000
Q2 2022 Aug 15, 2022	SELL	$17.22 - $38.47 $205,038 - $458,062	-11,907 Reduced 55.75%	9,449 $266,000
Q3 2021 Nov 15, 2021	SELL	$41.79 - $135.3 $12.1 Million - $39.3 Million	-290,182 Reduced 93.14%	21,356 $1.33 Million
Q2 2021 Aug 16, 2021	BUY	$32.15 - $89.72 $2.05 Million - $5.72 Million	63,809 Added 25.76%	311,538 $26.6 Million
Q1 2021 May 17, 2021	BUY	$7.09 - $87.95 $1.29 Million - $16 Million	182,351 Added 278.92%	247,729 $11.1 Million
Q4 2020 Feb 16, 2021	BUY	$6.79 - $12.25 $251,155 - $453,115	36,989 Added 130.29%	65,378 $446,000
Q3 2020 Nov 16, 2020	SELL	$2.86 - $11.51 $270,727 - $1.09 Million	-94,660 Reduced 76.93%	28,389 $327,000
Q2 2020 Aug 14, 2020	BUY	$2.04 - $9.64 $214,763 - $1.01 Million	105,276 Added 592.34%	123,049 $379,000
Q1 2020 May 15, 2020	BUY	$3.26 - $9.65 $57,939 - $171,509	17,773 New	17,773 $73,000
Q2 2019 Aug 14, 2019	SELL	$1.02 - $1.34 $21,145 - $27,779	-20,731 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$0.92 - $1.29 $19,072 - $26,742	20,731 New	20,731 $0

Others Institutions Holding SAVA

# of Institutions

189

Shares Held

13.5M

Call Options Held

1.38M

Put Options Held

2.26M

View Full List

About CASSAVA SCIENCES INC

Ticker SAVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,097,900
Market Cap $1.09B
Description
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...

More about SAVA

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account